Skip to main content
Fig. 6 | BMC Nephrology

Fig. 6

From: Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial

Fig. 6

Mean ± SD of ratio of SCr (final evaluation point/W0 [week 0 of the treatment period]): As shown in Table 5, both the 120 μg and the 240 μg groups showed an inhibition of the increase in SCr ratios as compared with the placebo group (P = 0.0309, 0.0204, respectively), assessed by ANCOVA with the SCr (R20) as covariate

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us